Literature DB >> 20471793

(Semi-)closed endarterectomy in occlusive aortoiliac disease.

Raoul van Vugt1, Rombout R Kruse, Steven M Sterkenburg, Wilbert M Fritschy, Frans L Moll.   

Abstract

BACKGROUND: Evaluation of the long-term results of a (semi-) closed endarterectomy of the aortoiliac segment with the use of the arterial disobliteration device.
METHODS: From 1984 until 2005, a total of 157 patients (mean age, 53 years) with aortoiliac occlusive disease underwent a (semi-)closed endarterectomy of the aortoiliac segment. The primary operation indication was disabling claudication in 60.5% and advanced symptoms of ischemia or gangrene in 39.5%. The (semi-) closed endarterectomy was performed in 75% through a standard left retroperitoneal approach.
RESULTS: Mean follow-up time was 18.2 years. Primary patency was 96% after 5 and 92% after 10 years. Fourteen patients underwent a reintervention within 30 days. The operative 30-day mortality rate was 1.5%. A reintervention for recurrence of occlusive disease during follow-up was necessary in 22 patients. At follow-up after an average of 18.2 years, 105 patients were alive, with 52 not related deaths.
CONCLUSION: Retroperitoneal (semi-) closed disobliteration, with the use of the arterial disobliteration device, of the aortoiliac segment for stenotic and occlusive vascular disease is a safe and successful procedure the results of which are comparable with the implantation of a vascular aortic prosthesis. We consider this technique a valuable tool in vascular surgery.
Copyright © 2010 Annals of Vascular Surgery Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20471793     DOI: 10.1016/j.avsg.2010.03.002

Source DB:  PubMed          Journal:  Ann Vasc Surg        ISSN: 0890-5096            Impact factor:   1.466


  1 in total

1.  Abdominal aortic occlusion of young adults.

Authors:  Federico Bucci; Leslie Fiengo; Samer Hamati; Philippe Plagnol
Journal:  Interact Cardiovasc Thorac Surg       Date:  2011-11-18
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.